NYSE:WSTLife Sciences
West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives
West Pharmaceutical Services (WST) just posted its FY 2025 third quarter scorecard, with revenue of US$804.6 million and basic EPS of US$1.94 setting the tone for the latest update. The company has seen revenue move from US$702.1 million in Q2 2024 to US$804.6 million in Q3 2025, while basic EPS has ranged from US$1.52 in Q2 2024 to US$1.94 in the latest quarter. This gives investors a clearer view of how the top line and per share earnings have tracked through the last six reported periods...